Dr. Reddy's Laboratories - Management Meet Update
We hosted the management of Dr. Reddy’s Laboratories Ltd at our Annual Investor Conference to discuss the business outlook. The company expects to...
196 Views
Dr. Reddy's Laboratories - Strong Growth Across Business Segments
We reiterate our Buy rating on Dr. Reddy’s Laboratories (DRL) with a target price (TP) of Rs5,424. 4QFY22 earnings performance was above expectations
207 Views
Dr Reddys Labs: Stable Results Despite Industry Headwinds; Maintain BUY
The company is building a global pipeline of biosimilars, developments of NCE for Immuno-oncology, and building up a Neutraceuticals portfolio,...
394 Views
Pharmaceutical Sector: Sequentially Flattish Quarter Expected
4QFY22 is expected to be a flattish quarter for most Pharma companies in our coverage universe. We expect a few companies to benefit from the US...
332 Views
HSIE Results Daily: DLF, Dr. Reddy’s, IndusInd Bank and More
HSIE Results Daily DLF: DLF surprised positively on presales at INR 10bn (6.6x/-5% YoY/QoQ) despite the lockdown during the quarter. While office...
92 Views